Despite the widespread use of antineoplastic platinum drugs, a number of accompanying
disadvantages exist. In connection with attempts to circumvent these problems new platinum …

Since the discovery of its anticancer activity in 1970s, cisplatin and its analogs have become
widely used in clinical practice, being administered to 40-80% of patients undergoing …

Cisplatin is a widely prescribed anticancer drug, which triggers cell death by covalent
binding to a broad range of biological molecules. Among cisplatin targets, cellular RNAs …

Cisplatin, one of the most widely used anticancer drugs, crosslinks DNA and ultimately
induces cell death. However, the genomic pattern of cisplatin–DNA adducts has remained …

The numerous regulatory roles of cellular RNAs suggest novel potential drug targets, but
establishing intracellular drug–RNA interactions is challenging. Cisplatin (cis …

Since its FDA approval just over 40 years ago, cisplatin and its more recently approved
analogues, carboplatin and oxaliplatin, have been widely used to treat a spectrum of …

Targeting nucleic acids with metal complexes is an exciting and widely explored field of
research. Following the discovery of the anticancer drug cisplatin, a number of metal …

New drug discovery strategies are emerging at a rapid pace to combat the threat of mortality
caused by various chronic diseases viz., HIV-AIDS, respiratory infections and cancers. The …

Oxaliplatin shows a superior clinical activity in colorectal cancer compared to cisplatin.
Nevertheless, the knowledge about its cellular distribution and the mechanisms responsible …

Methods to map small-molecule binding sites on cellular RNAs are important for
understanding interactions with both endogenous and exogenous compounds. Pt (II) …